Amygdalar glutamatergic neuronal systems play a key role on the hibernating state of hamsters.
BACKGROUND
Excitatory transmitting mechanisms are proving to play a critical role on neuronal homeostasis conditions of facultative hibernators such as the Syrian golden hamster. Indeed works have shown that the glutamatergic system of the main olfactory brain station (amygdala) is capable of controlling thermoregulatory responses, which are considered vital for the different hibernating states. In the present study the role of amygdalar glutamatergic circuits on non-hibernating (NHIB) and hibernating (HIB) hamsters were assessed on drinking stimuli and subsequently compared to expression variations of some glutamatergic subtype mRNA levels in limbic areas. For this study the two major glutamatergic antagonists and namely that of N-methyl-D-aspartate receptor (NMDAR), 3-(+)-2-carboxypiperazin-4-yl-propyl-1-phosphonate (CPP) plus that of the acid α-amine-3-hydroxy-5-methyl-4-isoxazol-propionic receptor (AMPAR) site, cyano-7-nitro-quinoxaline-2,3-dione (CNQX) were infused into the basolateral amygdala nucleus. Attempts were made to establish the type of effects evoked by amygdalar glutamatergic cross-talking processes during drinking stimuli, a response that may corroborate their major role at least during some stages of this physiological activity in hibernators.


RESULTS
From the behavioral results it appears that the two glutamatergic compounds exerted distinct effects. In the first case local infusion of basolateral complexes (BLA) with NMDAR antagonist caused very great (p < 0.001) drinking rhythms while moderately increased feeding (p < 0.05) responses during arousal with respect to moderately increased drinking levels in euthermics. Conversely, treatment with CNQX did not modify drinking rhythms and so animals spent more time executing exploratory behaviors. These same antagonists accounted for altered glutamatergic transcription activities as displayed by greatly reduced GluR1, NR1 and GluR2 levels in hippocampus, ventromedial hypothalamic nucleus (VMN) and amygdala, respectively, plus a great (p < 0.01) up-regulation of GluR2 in VMN of hibernators.


CONCLUSIONS
We conclude that predominant drinking events evoked by glutamatergic mechanisms, in the presence of prevalently down regulated levels of NR1/2A of some telencephalic and hypothalamic areas appear to constitute an important neuronal switch at least during arousal stage of hibernation. The establishment of the type of glutamatergic subtypes that are linked to successful hibernating states, via drinking stimuli, may have useful bearings toward sleeping disorders.
Comparative Neuroanatomy Laboratory of Ecology Department, University of Calabria, Ponte Pietro Bucci, 87030 Arcavacata di Rende, Cosenza, Italy.
Raffaella
R
Alò
Ennio
E
Avolio
Antonio
A
Carelli
Rosa Maria
RM
Facciolo
Marcello
M
Canonaco
D000679:Amygdala / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D006224:Cricetinae; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology; D006605:Hibernation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008647:Mesocricetus; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology*
D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA; D016194:Receptors, N-Methyl-D-Aspartate
Behav Brain Res. 2003 Mar 18;140(1-2):1-47
12644276
Behav Neurosci. 2000 Feb;114(1):84-98
10718264
Psychopharmacology (Berl). 2005 Apr;179(1):181-8
15821949
Physiol Rev. 2003 Jul;83(3):803-34
12843409
Behav Neurosci. 2006 Dec;120(6):1235-41
17201467
Regul Pept. 2006 Sep 11;136(1-3):58-63
16782213
Physiol Rev. 2003 Oct;83(4):1153-81
14506303
BMC Neurosci. 2009 Apr 06;10:32
19348678
Behav Brain Res. 2002 Oct 17;136(1):211-6
12385807
Dev Neurobiol. 2009 Feb 1-15;69(2-3):105-23
19086030
J Neurochem. 2004 Sep;90(5):1173-85
15312172
Brain Res Brain Res Rev. 2001 Dec;38(1-2):247-89
11750934
J Appl Physiol (1985). 2002 Jun;92(6):2640-7
12015384
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18775-80
17121986
Cell Tissue Res. 1997 Jun;288(3):441-7
9134858
Neuron. 1999 Feb;22(2):221-32
10069329
Glia. 2008 Jan 15;56(2):233-40
18046734
J Pharmacol Exp Ther. 2005 Oct;315(1):188-95
15976014
J Neurosci. 2005 Sep 28;25(39):8908-16
16192381
Brain Res. 2001 Dec 7;921(1-2):122-32
11720718
Lancet. 2003 Sep 27;362(9389):1028-37
14522533
J Appl Physiol (1985). 2001 Aug;91(2):603-12
11457771
Physiol Genomics. 2002 Aug 14;10(2):93-102
12181366
J Electron Microsc (Tokyo). 1999;48(6):957-69
10742960
Psychopharmacology (Berl). 2005 Apr;179(1):164-71
15619119
Annu Rev Physiol. 2004;66:239-74
14977403
J Neurosci. 2006 Feb 1;26(5):1331-3
16452656
Neurochem Int. 2006 Jun;48(8):753-61
16481069
Genes Brain Behav. 2004 Oct;3(5):253-65
15344919
Physiol Behav. 2002 May 1;76(1):117-29
12175595
J Neurochem. 2005 Jul;94(2):510-9
15998301
J Cereb Blood Flow Metab. 2006 Sep;26(9):1148-56
16395285
Am J Physiol. 1996 Feb;270(2 Pt 2):R443-9
8779877
Annu Rev Pharmacol Toxicol. 2003;43:335-58
12540744
J Neurosci. 2001 Jun 15;21(12):4207-14
11404406
Brain Res. 2009 Oct 13;1293:121-8
19328775
J Sleep Res. 2010 Sep;19(3):394-9
20374448
Neurosci Biobehav Rev. 2004 Jan;27(8):765-76
15019426
Brain Res. 1998 May 18;793(1-2):305-10
9630691
Behav Brain Res. 2007 Nov 22;184(1):91-100
17706799
Prog Neurobiol. 1999 Oct;59(3):279-98
10465381
Brain Res Bull. 2006 Dec 11;71(1-3):183-92
17113945
J Neurosci. 2008 Jan 2;28(1):68-79
18171924
Brain Res. 2000 Jun 30;869(1-2):15-24
10865054
J Comp Neurol. 2007 Dec 1;505(4):443-58
17912746
J Neurochem. 2007 Sep;102(6):1713-1726
17555547
J Neurosci Res. 2006 Aug 1;84(2):291-8
16676330
J Neurochem. 2008 Aug;106(4):1888-99
18624914
Curr Opin Pharmacol. 2007 Feb;7(1):39-47
17088105
J Pharmacol Exp Ther. 2005 Feb;312(2):826-33
15383637